Published in

American Association for the Advancement of Science, Science, 6532(371), 2021

DOI: 10.1126/science.abc8378

Links

Tools

Export citation

Search in Google Scholar

Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity

Journal article published in 2021 by Mads Delbo Larsen ORCID, Erik L. de Graaf ORCID, Myrthe E. Sonneveld, H. Rosina Plomp, Jan Nouta, H. Rosina Plomp, Willianne Hoepel ORCID, Hung-Jen Chen, Federica Linty, Remco Visser, Maximilian Brinkhaus, Tonći Šuštić, Steven W. de Taeye, Philip J. M. Brouwer, Arthur E. H. Bentlage and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

A single sugar makes all the difference Antibodies are divided into several classes based on their nonvariable tail (Fc) domains. These regions interact with disparate immune cell receptors and complement proteins to help instruct distinct immune responses. The Fc domain of immunoglobulin G (IgG) antibodies contains a conserved N-linked glycan at position 297. However, the particular glycan used at this position is highly variable. IgG lacking core fucosylation at this position initiates enhanced antibody-dependent cellular cytotoxicity by increased affinity to the Fc receptor FcRIIIa. Larsen et al. report that COVID-19 patients with severe symptoms have increased levels of anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG afucosylation compared with patients with mild disease. These findings suggest that treatment of COVID-19 patients with fucosylated anti–SARS-CoV-2 antibodies may circumvent pathologies associated with severe COVID-19. Science , this issue p. eabc8378